Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP R&D & MEDICAL AFFAIRS

SVP & CHIEF BUSINESS OFFICER

VP & PRIN ACCTG OFFICER

CHIEF EXECUTIVE OFFICER

SVP & CHIEF LEGAL OFFICER

SVP OF REGULATORY AFFAIRS

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) f...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	EVP R&D & MEDICAL AFFAIRS
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	-
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	SVP & CHIEF BUSINESS OFFICER
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	-
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	VP & PRIN ACCTG OFFICER
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	-
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	-
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	-
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	SVP & CHIEF LEGAL OFFICER
2024-02-12	Premium	back to issuer	Premium	Premium	Premium	SVP OF REGULATORY AFFAIRS
2024-02-05	Premium	sold	Premium	Premium	Premium	VP & PRIN ACCTG OFFICER
2024-02-05	Premium	sold	Premium	Premium	Premium	SVP OF REGULATORY AFFAIRS
2024-02-05	Premium	sold	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-02-05	Premium	sold	Premium	Premium	Premium	SVP & CHIEF BUSINESS OFFICER
2024-02-02	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-02-02	Premium	acquired	Premium	Premium	Premium	VP & PRIN ACCTG OFFICER
2024-02-02	Premium	acquired	Premium	Premium	Premium	SVP & CHIEF BUSINESS OFFICER
2024-02-02	Premium	acquired	Premium	Premium	Premium	SVP OF REGULATORY AFFAIRS
2024-01-16	Premium	acquired	Premium	Premium	Premium	SVP OF REGULATORY AFFAIRS
2024-01-16	Premium	sold	Premium	Premium	Premium	SVP OF REGULATORY AFFAIRS
2023-12-29	Premium	acquired	Premium	Premium	Premium	VP & PRIN ACCTG OFFICER
2023-12-29	Premium	acquired	Premium	Premium	Premium	SVP & CHIEF BUSINESS OFFICER
2023-12-29	Premium	acquired	Premium	Premium	Premium	-
2023-12-29	Premium	acquired	Premium	Premium	Premium	SVP OF REGULATORY AFFAIRS

IMGN - ImmunoGen Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for IMGN